We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOVT icon
276
iShares US Treasury Bond ETF
GOVT
$43.6B
– –
-20,000
Closed -$461K
KVUE icon
277
Kenvue
KVUE
$36.9B
– –
-53,293
Closed -$1.15M
MDGL icon
278
PUT
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-500
Closed -$116K
MRUS
279
DELISTED
Merus
MRUS
– –
-24,000
Closed -$660K
NAMSW icon
280
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
– –
-82,857
Closed -$259K
PFE icon
281
CALL
Pfizer
PFE
$153B
– –
-43,000
Closed -$1.24M
RFL icon
282
Rafael Holdings
RFL
$107M
– –
-2,397
Closed -$4.33K
ROIV icon
283
CALL
Roivant Sciences
ROIV
$26.2B
– –
-4,000
Closed -$44.9K
RVMD icon
284
Revolution Medicines
RVMD
$44B
– –
-400
Closed -$11.5K
RVPH
285
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-125
Closed -$12.9K
RYTM icon
286
CALL
Rhythm Pharmaceuticals
RYTM
$7.96B
– –
-1,000
Closed -$46K
SHY icon
287
iShares 1-3 Year Treasury Bond ETF
SHY
$25.1B
– –
-15,000
Closed -$1.23M
SLNO
288
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-1,100
Closed -$44.3K
THC icon
289
Tenet Healthcare
THC
$21.1B
– –
-2,000
Closed -$151K
UTHR icon
290
United Therapeutics
UTHR
$23.1B
– –
-8,000
Closed -$1.76M
YMAB
291
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-13,045
Closed -$89K
OKUR
292
OnKure Therapeutics
OKUR
$168M
– –
-4,000
Closed -$64K
GHIX
293
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
– –
-30,043
Closed -$315K
CETU
294
DELISTED
Cetus Capital Acquisition Corp. Class A Common Stock
CETU
– –
-5,000
Closed -$52.5K
TARO
295
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
– –
-200
Closed -$8.36K
ALPN
296
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-3,027
Closed -$57.7K
AYX
297
DELISTED
Alteryx Inc
AYX
– –
-62,038
Closed -$2.93M
KRTX
298
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-10,000
Closed -$3.17M
THRX
299
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-174,715
Closed -$708K
IMGN
300
CALL
DELISTED
Immunogen Inc
IMGN
– –
-2,000
Closed -$59.3K
9 10 11
12
13

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.